Director of Immunoncology R&D at Medimmune LLC
Dr. John Mumm received his PhD from MD Anderson Cancer Center where he discovered that IL-10 directly activates anti-tumor CD8+ T cells. John post-doc’ed at DNAX Research Institute and became a Scientist at Schering Plough where he develop PEGylated IL-10 (AM0010) as an immunoncology asset. He then founded Targenics, later called ARMO BioSciences, to clinically develop AM0010 and other IO assets. John is currently the Director of Immunoncology R&D at Medimmune LLC and is the author of 26 peer reviewed manuscripts and 14 granted or pending patents with over 20 years’ experience in the biotechnology field.